Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.37 |
| ▸ | MGMT | P16455 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1684047 | 0.85 | GDA (0.38) | GDAPARP1PNPGAA | |
| SCHEMBL8505965 | 0.84 | GDA (0.33) | GDAMGMT | |
| SCHEMBL9758969 | 0.81 | GDA (0.32) | GDA | |
| SCHEMBL9393663 | 0.80 | ADORA2A (0.46) | GDAMGMTGAATDP1L3MBTL1 | |
| SCHEMBL8506347 | 0.80 | GDA (0.34) | GDA | |
| SCHEMBL20508956 | 0.79 | TDP1 (0.37) | GAATDP1L3MBTL1 | |
| SCHEMBL14938903 | 0.78 | CYP1A2 (0.39) | GDAL3MBTL1 | |
| SCHEMBL453562 | 0.77 | POLB (0.44) | GAATDP1 | |
| SCHEMBL5468651 | 0.76 | XDH (0.41) | — | |
| SCHEMBL7640806 | 0.75 | KMT2A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2157182-A2 | Modified short interfering RNA | Qiagen GmbH (DE) | 2010-02-24 | — | — | EP | claimed |
| CN-113453707-A | RNA for malaria vaccine | 库瑞瓦格股份公司 | 2021-09-28 | — | — | CN | disclosed |
| US-8859749-B2 | Modified short interfering RNA | QIAGEN GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-2157182-A2 | Modified short interfering RNA | Qiagen GmbH (DE) | 2010-02-24 | — | — | EP | disclosed |
| US-20090197332-A1 | Modified Short Interfering RNA | QIAGEN GMBH (DE) | 2009-08-06 | — | — | US | disclosed |
| EP-1863912-A2 | MODIFIED SHORT INTERFERING RNA | Qiagen GmbH (DE) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006102970-A2 | MODIFIED SHORT INTERFERING RNA | QIAGEN GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1645561-A1 | METHOD OF SYNTHESIZING CYCLIC BISDINUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2006-04-12 | — | — | EP | disclosed |
| WO-1992011276-A1 | NOVEL SYNTHESIS OF 2'-'UP' FLUORINATED 2''-DEOXY-ARABINOFURANOSYLPURINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1992-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197332-A1 | Modified Short Interfering RNA | NSUN2, NSUN3, METTL16 | GDA 1238/4885MGMT 1172/4885PARP1 1390/4885 |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | GDA 716/4885MGMT 408/4885PARP1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.